638. Utility of Recombinant Hepatitis B Vaccine in Pre-liver Transplant Candidates

BACKGROUND: A recombinant, adjuvanted Hepatitis B (HBV) vaccine (HepB-CpG) was approved by the FDA in 2017. Initial FDA data showed greater immunogenicity than comparable recombinant HBV vaccines. Moreover, it requires only two doses over four weeks instead of three doses over six months, so there i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Jack, Prasad, Pooja, Weinberg, Amy, Bynon, John S, Machicao, Victor I, Nigo, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752585/
http://dx.doi.org/10.1093/ofid/ofac492.690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752585/
http://dx.doi.org/10.1093/ofid/ofac492.690

Ejemplares similares